Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Immediate improvement in pain relief Number of participants improved (good/very good efficacy) on a self assessed categorical 'overall efficacy score' (0 = no efficacy to 4 = very good) · patients with trigeminal neuralgia
Tizanidine showed no clear difference in immediate improvement in pain relief Number of participants improved… compared with carbamazepine (low certainty).
1 finding from 1 review
Intervention not reported
Impairment of activities of daily living (ADL) in glycogen storage disease type V Visual numeric scale. Scale from: 1 to 10. · patients with metabolic myopathies
1 finding from 1 review
Intervention not reported
Upper extremity maximum voluntary isometric contraction score at 3 months Quantitative Muscle Assessment (QMA) system. Data were normalized, summed and averaged to yield an U/E megascore (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Intervention not reported
Lower extremity maximum voluntary isometric contraction score at 3 months Quantitative Muscle Assessment (QMA) system. Data were normalized, summed and averaged to yield a L/E megascore (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Persistence of PHN among all subjects a numerical rating scale for pain1 · people at risk for postherpetic neuralgia
Vaccination leads to lower persistence of PHN among all subjects a numerical rating scale for… compared with placebo (high certainty).
1 finding from 1 review
Persistence of PHN among subjects developing herpes zoster a numerical rating scale for pain1 · people at risk for postherpetic neuralgia
Vaccination showed no clear difference in persistence of PHN among subjects developing herpes zoster a… compared with placebo (moderate certainty).
1 finding from 1 review
Change in maximal isometric voluntary contraction force (Nm) · patients with people with peripheral neuropathy
1 finding from 1 review
Muscle strength · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Change in Ejection fraction (%) · boys with DMD and left ventricular ejection fraction 45% or more
1 finding from 1 review
Size of metabolically abnormal areas of myocardium · boys with DMD and left ventricular ejection fraction 45% or more
1 finding from 1 review
Improvements in quality of life measures · boys with DMD and left ventricular ejection fraction 45% or more
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · boys with DMD and left ventricular ejection fraction 45% or more
It is very uncertain whether eplerenone (25 mg daily) changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Survival at 1 year Estimated survival at 1 year based on trials of 6 and 9 months' duration · people with ALS/MND
1 finding from 1 review